Drug intelligence / Profile preview

TOR-104

Development stage: Preclinical
Lead developer: Tornado Therapeutics
Modality: Small Molecules

Overview

TOR-104 is a small molecule drug candidate developed by Tornado Therapeutics. It functions as an inhibitor of the mechanistic target of rapamycin (mTOR), specifically acting as a serine/threonine-protein kinase mTOR inhibitor. The drug is being investigated for the treatment of autoimmune diseases and is currently in preclinical development. The goal of this class of drugs is to modulate immune system activity by inhibiting mTOR signaling, which plays a central role in cell growth, proliferation, and survival pathways relevant to immune function[1][2][3][4].

Targets

mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on TOR-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TOR-104.

Explore the full profile